ViewRay Inc., a Cleveland-based medical device company, has raised $15 million in fresh funding, raising the total amount raised by the company to nearly $100 million. The company’s machinery, which can produce real-time images of cancerous tumors while the tumors are being treated radiation, raised what has been in its biggest round, a $45 million Series C, last year. ViewRay’s investors include Aisling Capital, Fidelity Biosciences, Kearny Venture Partners, OrbiMed Advisors and Siemens Venture Capital.
You are browsing the archive for OrbiMed Advisors - peHUB.
San Diego-based Ambit Biosciences Corp., which discovers, develops and commercializes drugs to treat needs in oncology, autoimmune and inflammatory diseases, has priced its initial public offering at US$8.00 per share. Listing on NASDAQ under the symbol “AMBI,” the company plans to raise US$65 million. Ambit has since 2000 been backed by U.S. and Canadian venture capital firms, including Apposite Capital, Avalon Ventures, Forward Ventures, Genechem, GIMV, GrowthWorks, Horizon, MedImmune, NovaQuest, OrbiMed Advisors, Perseus-Soros, Radius Ventures and Roche Venture Fund.
Medigus, an Israel-based medical device company, has raised $8 million from OribMed Israel Partners LLC, an affiliate of the healthcare investment firm OrbiMed Advisors. In exchange, OrbiMed was issued 30.7 percent of Medigus’s shares.
This week peHUB is highlighting a handful of positions based in Boston, San Diego, New York and London.
Cardioxyl Pharmaceuticals has secured $28 million in a Series B financing led by OrbiMed Advisors. New investor Osage University Partners joined OrbiMed and returning investors New Enterprise Associates and The Aurora Funds in the financing.
Principia Biopharma Inc., a biopharmaceutical company focused on immunology, autoimmune diseases, and oncology, has raised $12.5 million. Investors include New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures, SROne and Mission Bay Capital.
arGEN-X BV has granted a worldwide exclusive license to RuiYi to develop and commercialize ARGX-109, a novel anti-IL-6 monoclonal antibody discovered and developed by arGEN-X. arGEN-X is backed by OrbiMed Advisors, Seventure Partners, Forbion Capital Partners, Credit Agricole Private Equity, LSP, BioGeneration Ventures, the Erasmus Biomedical Fund, Thuja Capital and VIB.
OmniGuide has closed a $35 million financing with OrbiMed Advisors. Cambridge, Mass.-based OmniGuide develops advanced energy surgical instruments. PRESS RELEASE OmniGuide Inc., a Cambridge, Massachusetts medical device company specializing in advanced energy surgical products, announced the closing of a $35 million non-dilutive financing with an affiliate of OrbiMed Advisors LLC. The financing structure allows OmniGuide [...]
AxioMed Spine Corporation, a spinal orthopedics company has closed its Series D financing, raising $5 million in two tranches from current and new investors. This funding boosts the previously announced $15 million Series D financing. Investors in the business include Siemens Venture Capital, Aisling Capital, Fidelity Biosciences, Kearny Venture Partners and OrbiMed Advisors. PRESS RELEASE [...]
Roka Bioscience has secured $47.5 million in Series D financing. New investor Aisling Capital participated in the financing along with existing investors OrbiMed Advisors, New Enterprise Associates and TPG Biotech. Josh Bilenker, MD, partner at Aisling Capital, will join Roka’s board of directors. Upon completion of theround, the total amount raised since the company’s formation [...]